The monkeypox vaccine, produced by the National Research Center for Epidemiology and Microbiology named after NF Gamaleya, is described as capable of providing long-lasting protection against the disease. The information is attributed to Alexander Ginzburg, the center’s director, in a report by TASS.
Ginzburg emphasized that achieving a durable immune response relies on a vaccine that uses a strong carrier, such as a genetically modified adenovirus. He also noted that a lack of antigenic drift in the monkeypox virus is crucial for long-term vaccine effectiveness, much like the considerations seen with influenza and SARS-CoV-2.
When asked about the need for revaccination, the expert suggested that immunity could persist for life, though such a conclusion would require ongoing verification and study.
Ginzburg drew a parallel to vaccination against coronavirus, suggesting that the same principle could apply to vaccines built on the original Sputnik V platform for the so-called Wuhan strain. He pointed to the potential for long-lasting immune memory, provided the vaccines maintain robust efficacy against circulating variants.
According to the center’s director, data from those who received the initial Sputnik V vaccination showed antibody levels rising to exceptionally high levels over time. He speculated that a similar trajectory could occur for vaccines targeting monkeypox or smallpox, assuming the vaccines remain well-matched to the virus and are produced under rigorous quality controls.
Earlier, the World Health Organization discussed the importance of masking during monkeypox outbreaks, highlighting nonpharmaceutical measures as part of a broader public health strategy. This guidance reflects the ongoing emphasis on layers of protection while surveillance and vaccination efforts continue to adapt to evolving epidemiology.